MOTS-c side effects and risks

Reported side effects

• Sleep disruption or feeling overstimulated: Forum reports only; no denominator or reliable rate., moderate. Stop use and review new insomnia or stimulation with a clinician. (source)
• Immune or allergic reactions: FDA identifies a potential risk; native peptide human incidence is unknown., serious. Breathing difficulty or swelling requires emergency care. (source)
• Injection-related infection or contamination: General unapproved injectable risk; no MOTS c specific rate., serious. Seek care for spreading redness, heat, pain or fever. (source)
• Painful or itchy injection-site swelling: Several forum comments; no reliable rate or confirmed product identity., moderate. Stop exposure and seek review for persistent swelling; breathing symptoms need emergency care. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, collapse: Stop exposure and call emergency services now. Use prescribed adrenaline if available.
• Spreading hot, painful injection-site redness, especially with fever: Stop injections and seek same-day care; confusion or fainting needs emergency care.
• Confusion, seizure, collapse or low blood sugar that does not resolve: Call emergency services for severe symptoms; follow the established diabetes rescue plan if applicable.

Who should avoid it

• pregnant: Precaution: no administered-peptide pregnancy safety data were identified.
• breastfeeding: Precaution: transfer into milk and effects on a nursing infant are unknown.
• tryingToConceive: Precaution: human fertility and embryo safety after injected peptide are unknown.
• under18: Precaution: no pediatric dosing or injection-safety data were identified.
• diabetes: Glucose effects and interactions with diabetes medicines are untested in humans.
• kidneyDisease: Human clearance and dose adjustment in kidney disease have not been established.
• liverDisease: Human exposure and dose adjustment in liver disease have not been established.
• heartCondition: Cardiac biomarker studies do not establish injection safety in people with heart disease.
• surgeryPlanned: Tell the care team about use; perioperative drug interactions and safety are unknown.
• activeCancer: No clinical cancer-treatment interaction data exist; laboratory effects cannot predict safety during cancer care.
• testedAthlete: Prohibited at all times under WADA 2026 S4.4.1, metabolic modulators.

Interactions

• Insulin and sulfonylureas: Possible added glucose lowering is theoretical. No human interaction study has measured the risk.
• Metformin and other glucose-lowering medicines: Combination effects on glucose, appetite and exercise tolerance are untested for injected MOTS-c.
• Anticoagulants and antiplatelets: No compound-specific interaction is established. Review injection-related bleeding risk with the prescriber.
• Other mitochondrial peptides: No human trial establishes the safety or benefit of stacking mitochondrial peptides. HNG is not native humanin.

Product quality risks

• Unapproved injectable products can have too much, too little or none of the stated ingredient.
• Possible contaminants include microbes, endotoxins, solvents, metals and particles; risk varies by batch.
• No independent market-wide test of native MOTS-c or humanin products was identified.